Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Bicycle Therapeutics plc

Market Cap 278M 243M 225M 210M 393M 26.26B 396M 2.67B 1.04B 12.91B 1.04B 1.02B 44.85B P/E 2026 *
-1.71x
P/E 2027 * -1.9x
Enterprise Value -234M -205M -189M -177M -332M -22.13B -334M -2.25B -875M -10.88B -879M -860M -37.79B EV / Sales 2026 *
-12.8x
EV / Sales 2027 * -8.95x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-4.10%
Current month-15.14%
1 month-12.53%
3 months-8.51%
6 months-44.65%
Current year-43.79%
1 week 3.96
Extreme 3.96
4.24
1 month 3.95
Extreme 3.95
4.74
Current year 3.95
Extreme 3.95
7.34
1 year 3.95
Extreme 3.95
9.18
3 years 3.95
Extreme 3.95
28.67
5 years 3.95
Extreme 3.95
62.08
10 years 3.95
Extreme 3.95
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 75 01/01/2009
Director/Board Member 57 01/09/2015
Director/Board Member 69 18/07/2019
Date Insider Type Main position Quantity % Market Cap.
04-02Sell

Chief Technology Officer

2,404 0.0063%
04-02Sell

Chief Financial Officer

901 0.0024%
04-02Sell

Chief Operating Officer

1,408 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-4.10%-46.36%-85.22% 278M
+0.05%+5.37%+70.90%+119.27% 56.65B
+4.00%+7.51%+63.67%+68.77% 47.49B
-0.77%-0.67%-15.34%-15.95% 22.81B
+2.93%+1.17%-3.97%+384.78% 21.37B
+1.30%+3.73%+27.10%-17.51% 16.12B
+1.27%+7.65%+23.80%-36.02% 15.56B
-1.08%-3.11%+27.20%+158.30% 12.91B
+3.30%+15.02%+133.24%+273.89% 12.86B
+1.43%-6.44%+21.49% - 11.67B
Average +1.19%+1.53%+30.17%+94.48% 21.77B
Weighted average by Cap. +1.49%+3.26%+44.62%+109.59%

Financials

2026 *2027 *
Net sales 18.24M 15.93M 14.74M 13.76M 25.83M 1.72B 26.01M 175M 68.15M 847M 68.46M 66.98M 2.94B 14.11M 12.33M 11.41M 10.65M 19.99M 1.33B 20.13M 136M 52.74M 656M 52.99M 51.84M 2.28B
Net income -154M -134M -124M -116M -218M -14.52B -219M -1.48B -574M -7.14B -577M -564M -24.8B -162M -142M -131M -122M -230M -15.34B -232M -1.56B -607M -7.54B -609M -596M -26.2B
Net Debt -512M -447M -414M -386M -725M -48.38B -730M -4.92B -1.91B -23.79B -1.92B -1.88B -82.64B -404M -353M -327M -305M -572M -38.19B -577M -3.88B -1.51B -18.78B -1.52B -1.48B -65.23B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
22/06/26 3.980 $ -0.50% 607,836
18/06/26 4.000 $ -0.99% 317,931
17/06/26 4.040 $ +0.50% 969,140
16/06/26 4.020 $ -3.13% 947,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.980USD
Average target price
12.62USD
Spread / Average Target
+217.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!